CEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.

Original title: “Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya”

A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.

Original title: “Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand”

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

Original title: “This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking”

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

Original title: “BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs”

Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.

Original title: “Varda raises $251M to leverage gravity in space for drug production”

Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.

Original title: “Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen”

The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.

Original title: “HHS kicks off new programs to speed clinical trials as Chinese competition looms”

Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietary portfolio programs.

Original title: “Foghorn lays off 40% of staff after Lilly collaboration ends”

Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.

Original title: “US government launches AI-driven programs to overhaul clinical trials”

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

Original title: “5 FDA decisions to watch in the fourth quarter of 2026”

Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupixent.

Original title: “Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor”

Deal adds bioanalytical expertise in Australia

Original title: “Novotech to acquire Agilex Biolabs”

Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are each expected to gain over 200 jobs. Tax incentive award recipients include AstraZeneca, Bristol Myers Squibb and Insulet.

Original title: “$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts”